These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11234074)

  • 1. ADHD: disorder or discipline problem?
    Faraone SV; Biederman J
    Science; 2001 Feb; 291(5508):1488-9. PubMed ID: 11234074
    [No Abstract]   [Full Text] [Related]  

  • 2. What exactly are the benefits of stimulants for ADHD?
    Advokat C
    J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
    [No Abstract]   [Full Text] [Related]  

  • 3. Physician handling of prescription stimulants.
    Croft HA
    Pediatr Ann; 2006 Aug; 35(8):557-62. PubMed ID: 16986450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADHD: monitoring for and managing stimulant adverse effects.
    Mercer M; Farver D
    S D Med; 2013 Dec; 66(12):511, 513. PubMed ID: 24527549
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of attention deficit/hyperactivity disorder and the use of stimulants in prison. Evaluation of the risks and benefits.
    Fructuoso A
    Rev Esp Sanid Penit; 2019; 21(2):113-114. PubMed ID: 31642863
    [No Abstract]   [Full Text] [Related]  

  • 8. An update on attention deficit disorder.
    Harv Ment Health Lett; 2004 May; 20(11):4-7. PubMed ID: 15153391
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.
    Biederman J; Wilens T; Mick E; Spencer T; Faraone SV
    Pediatrics; 1999 Aug; 104(2):e20. PubMed ID: 10429138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention deficit hyperactivity disorder and substance use disorders.
    Bukstein OG
    Curr Top Behav Neurosci; 2012; 9():145-72. PubMed ID: 21789746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention deficit/hyperactivity disorder across the lifespan.
    Wilens TE; Biederman J; Spencer TJ
    Annu Rev Med; 2002; 53():113-31. PubMed ID: 11818466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulant treatment for ADHD may not increase risk of substance abuse.
    Harv Ment Health Lett; 2008 Jun; 24(12):7. PubMed ID: 18946888
    [No Abstract]   [Full Text] [Related]  

  • 13. Does the medicating ADHD increase or decrease the risk for later substance abuse?
    Wilens TE
    Braz J Psychiatry; 2003 Sep; 25(3):127-8. PubMed ID: 12975683
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment on Lambert and Hartsough (1998).
    Mick E; Biederman J; Faraone SV
    J Learn Disabil; 2000; 33(4):314; author reply 314-6. PubMed ID: 15493092
    [No Abstract]   [Full Text] [Related]  

  • 15. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).
    Kollins SH
    Am J Addict; 2007; 16 Suppl 1():35-42; quiz 43-4. PubMed ID: 17453605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Questioning the treatment for ADHD.
    Baughman FA
    Science; 2001 Jan; 291(5504):595. PubMed ID: 11229400
    [No Abstract]   [Full Text] [Related]  

  • 17. Stimulant treatment for ADHD.
    Verma R; Apala ; Kumari S; Dhiman V
    Br J Psychiatry; 2014 Jun; 204(6):490. PubMed ID: 25029692
    [No Abstract]   [Full Text] [Related]  

  • 18. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder.
    Groenman AP; Oosterlaan J; Rommelse NN; Franke B; Greven CU; Hoekstra PJ; Hartman CA; Luman M; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Br J Psychiatry; 2013 Aug; 203(2):112-9. PubMed ID: 23846996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD.
    Kantak KM; Dwoskin LP
    Pharmacol Biochem Behav; 2016 Jun; 145():24-6. PubMed ID: 27012495
    [No Abstract]   [Full Text] [Related]  

  • 20. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.